> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Since Our Last Issue ...
- URL: https://www.fdaweb.com/since-our-last-issue-42/
- Published: 2021-08-29T12:00:00.000Z
- Updated: 2026-09-14T17:12:18.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5138909

**SciClone Pharmaceuticals** has agreed to be acquired for $605 million by a consortium of buyers, including **GL Capital Management CP**, **Bank of China Group Investment**, and **Ascendent Capital Partners**. SciClone is a specialty pharmaceutical company with significant commercial business in China. Its portfolio covers oncology, infectious diseases and cardiovascular disorders. Its lead product is Zadaxin (thymalfasin) for hepatitis B, hepatitis C and some cancers, and is approved in over 30 countries.

**Valeant Pharmaceuticals** has entered into an agreement to sell its **iNova Pharmaceuticals** business to a company jointly owned by funds advised and managed by **Pacific Equity Partners** and **The Carlyle Group** for $930 million in cash. iNova, which markets prescription and over-the-counter products in several areas, such as weight management, pain management, cardiology and cough and cold, and operates in more than 15 countries around the world.

**Allergan** says it will acquire medical device developer **Keller Medical** for an undisclosed sum. The privately held medical device company which developed the Keller Funnel, a cone-shaped, lubricated plastic funnel designed to reduce surgeon and patient contact during breast augmentation or reconstruction procedures. The device was originally launched in 2009, with a next-gen version released in 2014.